IM Cannabis (IMCC) Consolidated Net Income (2020 - 2026)
IM Cannabis' (IMCC) quarterly Consolidated Net Income came in at -$1.8 million in Q1 2026, down 1575.03% year-on-year from $121960.4 in Q1 2025, and up 68.11% quarter-over-quarter from -$5.6 million in Q4 2025.
IM Cannabis (IMCC) Consolidated Net Income (2020 - 2026) Analysis & Trends
IM Cannabis' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- On a quarterly basis, Consolidated Net Income fell 1575.03% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$10.4 million, a 158.09% decrease from a year earlier, with the FY2025 full-year figure at -$8.4 million, changed N/A from the prior year.
- Consolidated Net Income advanced to -$1.8 million in Q1 2026 per IMCC's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $2.9 million in Q1 2022 and bottomed at -$94.8 million in Q3 2022.
- The 5-year median for Consolidated Net Income is -$2.3 million (2026), against an average of -$9.5 million.
- Biggest YoY gain for Consolidated Net Income was 102.73% in 2025; the steepest drop was 2553.06% in 2025.
- Year by year, Consolidated Net Income stood at -$17.5 million in 2022, then advanced by 29.04% to -$12.4 million in 2023, then jumped by 98.29% to -$212607.2 in 2024, then sank by 2553.06% to -$5.6 million in 2025, then soared by 68.11% to -$1.8 million in 2026.
- Per Business Quant, the three latest IMCC Consolidated Net Income figures stand at -$1.8 million (Q1 2026), -$5.6 million (Q4 2025), and -$2.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -5.64 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -137,847.09 |
| Mar 31, 2025 | 121,960.38 |
| Dec 31, 2024 | -212,607.19 |
| Sep 30, 2024 | -793,163.79 |
| Jun 30, 2024 | -3.14 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | -664,247.34 |
| Dec 31, 2022 | -17.53 Mn |
| Sep 30, 2022 | -94.80 Mn |
| Jun 30, 2022 | -11.98 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | -3.27 Mn |
| Sep 30, 2021 | -5.15 Mn |
| Jun 30, 2021 | -4.14 Mn |
| Mar 31, 2021 | 3.73 Mn |